Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECa 233 in Acute Temporomandibular Disorder
NCT06231212Phase 3Completed
- Sponsor
- Chulalongkorn University
- Start
- Aug 2020
- Primary completion
- Sep 2021
- Modality
- NHE (Natural Herbal Extract)
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ECa 233 in temporomandibular joint disorders (TMD) (4 arms), sponsored by Chulalongkorn University. Primary endpoints: Pain Intensity Score at 14 days, Jaw Functional Movements at 14 days and 1 more. Started Aug 2020; status: completed.
02
Drugs
ECa 233
03
Conditions
temporomandibular joint disorders (TMD)
Beyond the preview
Go deeper on NCT06231212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06231212.